Gökhan ÇAKIRCA, NURİYE METE, Ibrahim BATMAZ, Mustafa Akif SARIYILDIZ, Mehmet Ali ULU, Levent YAZMALAR, TAHSİN ÇELEPKOLU, Remzi ÇEVİK

The relationship between bone mineral density and levels of RANKL, osteoprotegerin and cathepsin-K in patients with rheumatoid arthritis

Amaç: Bu çalışmanın amacı Romatoid Artrit’li (RA) hastalarda Osteoprotegerin (OPG), Nükleer faktör kappa B reseptör aktivatörü ligandı (RANKL), katepsin-K düzeylerini ve ayrıca bu parametrelerin kemik mineral yoğunluğu (BMD) ile ilişkisini araştırmaktır. Gereç ve yöntem: Çalışmaya postmenopozal sağlıklı (n=30), postmenopozal osteoporozlu (n=30) ve postmenopoz RA’lı (n=30) toplam 90 olgu alındı. Serum RANKL, OPG ve katepsin-K ELİSA yöntemiyle çalışıldı. Bulgular: Postmenopozal RA’ lı hastalarda serum RANKL ve OPG seviyeleri postmenopozal sağlıklı kontrollere kıyasla anlamlı yüksekken, serum OPG/RANKL oranı anlamlı düşük bulundu. Bununla birlikte postmenopozal RA’lı hastalarda, postmenopozal osteoporozlu hastalara göre serum OPG ve OPG/RANKL oranı anlamlı düşük iken, serum RANKL seviyesi anlamlı yüksekti. Postmenopozal RA’lı hastalarda lomber spine (LS) ve femur neck (FN) kemik mineral dansiteleri (BMD) ile OPG/RANKL oranı arasında pozitif korelasyon saptanırken; RANKL düzeyleri ile negatif korelasyon bulundu. Sonuç: RANKL/RANK/OPG sistemi osteoporoz ve RA patogenezinde rol alabilmektedir ve OPG/RANKL oranı kemik dansitesinin önemli bir belirleyicisi olabilir.

Romatoid artritli hastalarda RANKL, osteoprotegerin ve katepsin-K düzeylerinin kemik mineral yoğunluğu arasında ilişki

Objectives: The aim of this study was to evaluate the levels of osteoprotegerin (OPG), nuclear factor kappa B receptor activator ligand (RANKL), cathepsin K in patients with rheumatoid arthritis (RA) and the relation between these parameters and bone mineral density (BMD). Materials and methods: Totally 90 cases including 30 postmenopausal and healthy women, 30 with postmeno-pausal osteoporosis and 30 with postmenopause RA were enrolled in the study. The serum RANKL, OPG and cathepsin K were measured by ELISA method. Results: The levels of serum RANKL and OPG in the pa- tients with postmenopausal RA were found significantly higher compared to the postmenopausal healthy women whereas the rate of serum OPG/RANKL was found sig- nificantly lower. In addition, the rate of OPG and OPG/ RANKL were significantly lower in patients with post- menopausal RA compared to the postmenopausal osteo- porosis, whereas the level of serum RANKL was signifi- cantly higher. Positive correlation was detected between bone densities of lumbar spine (LS), femur neck (FN) and the rate of OPG/RANKL in patients with postmenopausal RA. Also negative correlation was detected between LS and FN bone densities and RANKL levels. Conclusions: The system of RANKL/RANK/OPG may have a role in osteoporosis and RA pathogenesis and the rate of OPG/RANKL might be a significant determiner of bone density.

PDF

___

1. Armas LA, Recker RR. Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol Metab Clin North Am 2012;41(3):475-86.
2. Delmas PD. The role of markers of bone turnover in the assesment of fracture risk in postmenopausal women. Osteoporos Int 1998;8(S1):32-6.
3. Kurban S, Mehmetoğlu İ. Osteoprotegerin RANK and RANKL. Turk J Biochem 2007;32(3);178-84.
4. Kostenuik PJ, Shalhoub V. Osteoprotegerin: A Physiological and Pharmacological Inhibitor of Bone Resorption. Curr Pharm Des 2001;7(8):613-35.
5. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Therap 2007;9(S1):1-7.
6. McClung M. Role of RANKL inhibition in osteoporosis. Arthritis Res Therap 2007;9 (S1):S3.
7. Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor-kB (RANK)/RANK ligand/os- teoprotegerin: clinical implications. J Clinical Endocrinol Metab 2007;92(12):4514-21.
8. Romas E, Sims NA, Hards DK, et al. Osteoprotegerin re- duces osteoclast numbers and prevents bone erosion in col- lageninduced arthritis. Am J Pathol 2002;161(4):1419-27.
9. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43(2):250-8.
10. Baud’huin M, Lamoureuxa F, Duplomba L, et al. RANKL, RANK, osteoprotegerin: key partners of osteoimmünology and vascular diseases. Cell Mol Life Sci 2007;64(18):2334-50.
11. Hou WS, Li Z, Gordon RE, et al. Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol 2001;159(6):2167-77.
12. Goto T, Yamaza T, Tanaka T. Cathepsins in the osteoclast. J Electron Microsc. 2003;52(6):551-8.
13. Rieman DJ, McClung HA, Dodds RA, et al. Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone 2001;28(3):282-9.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheuma¬tism Association 1987 criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24.
15. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272(40):25190-4.
16. Haynes DR, Crotti TN, Capone M, et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 2001;40(6):623-30.
17. Nosaka K, Miyamoto T, Sakai T, et al. Mechanism of hy- percalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor jB ligand on adult T-cell leukemia cells. Blood 2002;99(2):634-40. Dicle Tıp Derg / Dicle Med J
18. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patient with rheumatoid arthritis: result from 394 patients in the Olso county rheumatoid arthritis register. Arthritis Rheum 2000;43(3):522-30.
19. Urbanek R, Tlustochowicz W, Patola J, et al. Incidence of osteoporosis in patients with rheumatoid arthritis. Przegl Lek 2000;57(2):103-7.
20. Oelzner P, Franke S, Lehmann G, et al. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol 2007;26(12):2127-35.
21. Xu S, Wang Y, Lu J and Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteo-porosis. Rheumatol Int 2011,DOI 10.1007/s00296-011- 2175-5.
22. Lodder MC, De Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 2004;63(12):1576-80.
23. Cohen SB, Dore RK, Lane NE, et al. The Denosumab Rheumatoid arthritis Study Group Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58(5):1299-309.
24. Skoumal M, Kolarz G, Woloszczuk W, et al. Serum cathepsin K levels of patients with destructive rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther 2005;7(1):65-70.